Contents lists available at ScienceDirect

Physics and Imaging in Radiation Oncology

journal homepage: www.sciencedirect.com/journal/physics-and-imaging-in-radiation-oncology

Original Research Article

Monte Carlo simulated correction factors for high dose rate brachytherapy postal dosimetry audit methodology

Krzysztof Chelminski^{a,*}, Alexis Dimitriadis^a, Roua Abdulrahim^a, Pavel Kazantsev^a, Evelyn Granizo-Roman^a, Jonathan Kalinowski^{b,c}, Shirin Abbasi Enger^{b,c}, Godfrey Azangwe^a, Mauro Carrara^a, Jamema Swamidas^a

^a International Atomic Energy Agency, Department of Nuclear Sciences and Applications, Division of Human Health, Vienna, Austria

^b McGill University, Department of Oncology, Medical Physics Unit, Montreal, Canada

^c Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada

ARTICLE INFO

Keywords: Brachytherapy Monte Carlo simulations Dosimetry audit Reference Air Kerma Rate

ABSTRACT

Background and Purpose: Full-scatter conditions in water are impractical for postal dosimetry audits in brachytherapy. This work presents a method to obtain correction factors that account for deviations from full-scatter water-equivalent conditions for a small plastic phantom.

Material and Methods: A 16 × 8 × 3 cm phantom (PMMA) with a radiophotoluminescent dosimeter (RPLD) at the centre and two catheters on either side was simulated using Monte Carlo (MC) to calculate correction factors accounting for the lack of scatter, non-water equivalence of the RPLD and phantom, source model and backscatter for HDR 60 Co and 192 Ir sources.

Results: The correction factors for non-water equivalence, lack of full scatter, and the use of PMMA were 1.062 ± 0.013 , 1.059 ± 0.008 and 0.993 ± 0.009 for 192 Ir and 1.129 ± 0.005 , 1.009 ± 0.005 and 1.005 ± 0.005 for 60 Co respectively. Water-equivalent backscatter thickness of 5 cm was found to be adequate and increasing thickness of backscatter did not have an influence on the RPLD dose. The mean photon energy in the RPLD for four HDR 192 Ir sources was 279 ± 2 keV in full scatter conditions and 295 ± 1 keV in the audit conditions. For 60 Co source the corresponding mean energies were 989 ± 1 keV and 1022 ± 1 keV respectively.

Conclusions: Correction factors were obtained through the MC simulations for conditions deviating from TG-43, including the amount of back scatter, and the optimum audit set up. Additionally, the influence of different source models on the correction factors was negligible and demonstrates their generic applicability.

1. Introduction

Cervical cancer is the fourth most common cancer among women globally, whereas about 90% of the new cases and deaths worldwide in 2020 occurred in low-and middle-income countries [1]. Brachytherapy has an essential role in treating cervical cancer [2]. High Dose Rate (HDR) brachytherapy delivers the prescribed dose to the tumour at a very high dose rate of > 12 Gy/h, with a high dose per fraction (e.g., ~ 7 Gy for typical fractionation schemes in cervical cancer), and if applied incorrectly can lead to under or over-dosage with the potential for adverse clinical effects. Ensuring consistent dose delivery is crucial to the quality and safety of this treatment option. This can also build public confidence in brachytherapy, which has been undermined by past reported incidents, including one fatality that was attributed to human

error [3]. Dosimetry audits can prevent catastrophic incidents and minimize systematic dose variations [4–6].

Audits are not as widely available in brachytherapy as in external beam radiotherapy (EBRT), which has advanced imaging and higher automation. This could potentially render EBRT a safer option compared to brachytherapy.

The current work is part of a project aiming at developing a multilevel dosimetry audit methodology for HDR brachytherapy starting with an evaluation of the Reference Air Kerma Rate (RAKR), followed by an end-to-end audit of the entire workflow including imaging, treatment planning and delivery using clinical applicators.

The objective of this paper was to explore a phantom design for auditing the RAKR through dose measurements by:

* Corresponding author. E-mail address: k.chelminski@iaea.org (K. Chelminski).

https://doi.org/10.1016/j.phro.2024.100657

Received 29 May 2024; Received in revised form 7 October 2024; Accepted 15 October 2024 Available online 22 October 2024





^{2405-6316/© 2024} The Author(s). Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

- a. determining an optimal audit set up for participating hospitals,
- b. determining correction factors for conditions deviating from fullscatter water-equivalent conditions (TG-43) [7] using Monte Carlo (MC) simulations, and
- c. evaluating spectral variations within the dosimeter for different ¹⁹²Ir and ⁶⁰Co HDR source models, with the aim to assess their influence on correction factors.

2. Materials and methods

2.1. Phantom and RPLD detector

A simple, light-weight, cost-effective phantom was proposed suitable for remote postal dosimetry audits to assess the agreement between the RAKR of the source in afterloader and in the treatment planning. As this phantom deviates from full-scatter water-equivalent conditions, a characterization was required to determine an optimal audit setup with appropriate correction factors. A phantom with outer dimensions of 16 \times 8 \times 3 cm (Fig. 1a), was designed to house a radiophotoluminescent dosimeter (RPLD) at its center (Fig. 1b). The phantom had two channels on either side of the RPLD that were 15 cm in length and 2 mm in diameter to accommodate catheters of 1.7–2.0 mm diameter (5–6 Fr). The catheters were positioned symmetrically to the centre and 4 cm apart, along the long axis of the phantom. Poly Methyl Methacrylate (PMMA) was considered as a material of choice as it was cost-effective, transparent, robust, and readily available. The RPLD (Fig. 1b) was made of silver-activated phosphate glass (GD-302 M, FD-7 glass Chivoda Technol Corporation, Japan [8]), of 1.5 mm diameter and 12 mm length, encapsulated in a watertight capsule made of high-density polyethylene (HDPE-M5001 MISATO Precision Inc., Nipolon Hard 2000, Tosoh Corporation, Japan [9]) which ensured convenient storage, transport and irradiation. The physical and chemical properties of the RPLDs used in the current study were given in Table 1 [10].

2.2. Treatment plan and radiation sources

The treatment plan consisted of 13 uniform source dwell positions in each catheter with a step size of 5 mm (Fig. 1). This plan geometry was chosen to produce a homogeneous dose distribution within the RPLD volume [11]. A dose of 2 Gy was prescribed to the centre of the RPLD (Fig. 2). The dose distribution was calculated using the TG-43 formalism (SagiPlan v2.1, BEBIG Medical Germany). The planning RAKR was set at 10 mGy/h and the corresponding dwell times were 16.04 s and 16.43 s for the ¹⁹²Ir (Bebig-GI192M11) and ⁶⁰Co (Bebig-Co0.A86) sources

Table 1

Material compositions and densities of simulated phantom and structure volumes.

Material (structure)	Density (g/cm ³)	Stochiometric formula	Atomic composition
G4_AIR	$1.2\times 10^{\text{-}3}$	-	C(0.01%), N(75.5%), O (23.2%), A(1.3%) [16]
G4_WATER	1.00	H ₂ O	H(11.2%), O(88.8%) [16]
G4_STAINLESS- STEEL (table)	8.00	-	Fe(74.0%), Cr(18.0%), Ni (8.0%) [16]
PMMA (phantom)	1.19	$C_5H_8O_2$	C(60.0%), H(8.0%), O (32.0%) [17]
HDPE (RPLD capsule)	0.96	C_2H_4	C(14.4%), H(85.6%)
FD-7 (RPLD glass)	2.61	_	Ag(0.17%), Al(6.12%), Na (11.0%), P(31.55%), O (51.16%) [10]
PA12 Polyamide (catheter)	1.01	C ₁₂ H ₂₃ NO	C(73.0%), H(11.8%), N (7.1%), O(8.1%)

respectively. The plan was exported in DICOM-RT format to perform all MC simulations [12].

2.3. MC simulation setup and software

The phantom, detector and backscatter material were delineated (Eclipse v15, Varian Palo Alto, USA), and exported in DICOM–RT format to RapidBrachyMCTPS [13]. The structure set, materials and densities assigned were shown in Table 1.

The Geant4 simulation toolkit (v.10.02.p02) was used through RapidBrachyMCTPS either on a local workstation or on a remote highperformance computer system (Compute Canada) [14] (Supplementary Table 1). For the dose distribution review and analysis, the Voxel Interactive Contour Tool for Online Radiation Intensity Analytics (VICTORIA) viewer was used [15]. A resolution of 1 mm in the axial direction and 1.25 mm in the sagittal and coronal directions per voxel was used for a 37 \times 37 \times 33 cm^3 simulation volume. All doses were scored as the mean and the standard deviation along the 6 mmlong central axial profile through the voxels within the active volume of the RPLD (Fig. 1b).

2.4. Optimal audit setup

While the proposed compact phantom might be a convenient geometry for irradiating dosimeters in a postal audit setting, the optimal



Fig. 1. a) A schematic representation of the proposed brachytherapy dosimetry audit phantom with two channels for inserting catheters with 13 active source dwell positions indicated on either side of the RPLD and b) a larger schematic representation of the RPLD, HDPE capsule and the six voxels representing the sensitive volume used to determine the dose in MC simulations.



Fig. 2. The schematic dose (Gy) distribution in the axial -XY and the coronal -XZ plane shows the 2.0 Gy -100% isodose crossing the prescription point corresponding the location of the RPLD.

setup for this phantom had not been determined. The setup options considered included placing the phantom in a water tank with near fullscatter conditions, placing the phantom on a table with partial/ controlled scatter conditions, or placing the phantom "in air" with almost complete lack of scatter beyond the phantom. While placing the phantom in water would have meant that the irradiation was closer to TG-43 conditions, this setup was considered impractical, and it was discarded. The phantom "in air" option, previously used with jigs for RAKR verification with a Farmer chamber (an alternative to the use of well-type chambers still used in some countries, although not recommended [18] was also discarded as an impractical setup where the audit participant would have to place the phantom on large amounts (at least 50 cm) [19] of low-density material, such as foam, or suspend the phantom using other not standardized supports. Finally, placing the phantom on a table was considered, as it was a dry and convenient setup with the catheters and transfer tubes in near-clinical orientation. However, the amount of scatter contributions to the dose might be difficult to control due to influences from different table materials among the participants. This issue might be potentially mitigated by placing the phantom on a slab of a specific thickness and material, which was a hypothesis for investigation. A readily available material in most radiotherapy centres was water equivalent slabs, therefore, varying thicknesses (5, 10 and 15 cm) of water equivalent slabs (G4_WATER) were simulated between the phantom and the table [16]. Additionally, to simulate worst case scenarios for different tables, a low-density table represented by a 3 mm layer of air (G4_AIR) and high-density table represented by a 3 mm layer of steel (G4_STAINLESS-STEEL) were simulated under the water equivalent slabs. The setup shown in Fig. 3a with varying thickness of G4_WATER backscatter material and with high- or low-density (G4_STAINLESS-STEEL or G4_AIR) SUPPORT

materials was used for these simulations.

From the simulations in auditing conditions (Fig. 3a), the following doses (D_a) were extracted:

 ${}^{5l}D_a$, ${}^{10l}D_a$, ${}^{15l}D_a$ – Doses to the RPLD with water-equivalent back scatter material of 5, 10 and 15 cm thickness between the phantom and the table made of low-density (*l*-index) material of thickness of 3 mm represented by air.

 ${}^{5h}D_a$, ${}^{10h}D_a$, ${}^{15h}D_a$ – Doses to the RPLD with water-equivalent back scatter material of 5, 10 and 15 cm thickness between the phantom and the table made of high-density (*h*-index) material of thickness of 3 mm represented by steel.

2.5. Phantom correction factors

The correction factors for the optimal setup were obtained by simulating the four scenarios shown in Fig. 3, following the methodology proposed by Bouchard et al. [20]. Fifty million (5×10^6) primary particles were simulated for 3.67–6.65 hr with two Intel Platinum 8260 Cascade Lake @2.40 GHz central processing units CPUs (Supplementary Table 1) [21]. Uncertainty of dose simulated in RPLD volume was calculated as standard deviation of dose from six adjacent voxels in the RPLD volume. Uncertainties of the correction factors were estimated using a differential method assessing sensitivities for uncertainties of doses [22].

Three correction factors were derived to determine the dose to water for the audit-setup:

- k_p perturbation caused by the non-water equivalence of the RPLD and its capsule,
- 2) k_m non-water equivalence of the phantom material,



Fig. 3. The MC simulated scenarios: a) The PMMA phantom placed on a water equivalent slab with a table underneath, b) the PMMA phantom in full-scatter water equivalent conditions, c) the RPLD and its capsule without a phantom in full-scatter water equivalent conditions, d) a water-equivalent RPLD in full-scatter water equivalent conditions.

3) k_s – lack of scatter for the phantom positioned on a table.

Detector (RPLD) perturbation correction factor k_p :

$$k_p\equiv D_w/D_{r,w}$$

where, D_w was the dose to a water-equivalent RPLD volume in full scatter conditions (Fig. 3d), and $D_{r,w}$ was the dose to the RPLD in water in full scatter conditions (Fig. 3c).

Phantom non-water equivalence correction factor k_m :

$$k_m \equiv D_{r,w}/D_{r,p}$$

where, $D_{r,p}$ was the dose to the RPLD in the PMMA phantom in full scatter conditions (Fig. 3b).

Lack of scatter correction factor ks:

 $k_s \equiv D_{r,p}/D_a$

where, D_a was the dose to RPLD in the PMMA phantom placed on a water equivalent back scatter slab, in audit conditions (Fig. 3a).

Applying the correction factors, the absorbed dose to water in the RPLD could be determined:

 $D_w = k_p \cdot k_m \cdot k_s \cdot D_a$.

2.6. Radiation spectrum analysis

RPLDs exhibit energy dependence [23,24], therefore an investigation was conducted to assess the changes in the energy spectrum when using different source models. This investigation was conducted to determine if the correction factors obtained for a specific source model could be applied to measurements with other source models. The energy spectra reaching the RPLD volume were simulated for the most popular HDR source models presented in <u>Supplementary Table 2 [25]</u>. Two geometries were simulated for comparison:

- 1) the RPLD in full scatter conditions, implementing the physical properties of FD-7 for the glass and HDPE for the capsule (Table 1) at the centre of a $37 \times 37 \times 33$ cm³ water cube (Fig. 3c), and
- 2) the proposed audit setup with the phantom on a 5 cm thick water equivalent slab with the RPLD inside the phantom (Fig. 3a).

One million (10⁶) primary particles were simulated for 7–13 min using a CPU of Lenovo ThinkCentre M720s desktop computer (Supplementary Table 1) [21]. Energy of each particle reaching the RPLD active volume was scored. The simulation was repeated five times. The mean energy of particles was calculated and assumed as an index of the radiation quality reaching RPLD. The uncertainty for the mean energy of particles was calculated using the batch method for results from five simulation runs [26].

3. Results

3.1. Optimal audit setup

The results of simulations with the phantom in all table setups were shown in the top section of Table 2. The varying thicknesses of water slabs between the phantom and the two table materials simulated did not show a significant impact on the RPLD dose with values ranging from 1.776 to 1.785 Gy (¹⁹²Ir) and from 1.731 Gy to 1.733 Gy (⁶⁰Co) for both air and steel with all results falling within the simulation uncertainties. The mean (\pm standard deviation) RPLD dose of all audit setups was $D_a = 1.781 \pm 0.012$ Gy for ¹⁹²Ir, and $D_a = 1.733 \pm 0.006$ Gy for ⁶⁰Co. The results suggested that a 5 cm water equivalent slab used as backscatter was sufficient to mitigate any potential impact the underlying table might have on scatter conditions, and subsequently on the dose to the RPLD.

Table 2

Simulated doses in Gy and correction factors for different setups for the $^{192}\rm{Ir}$ (Bebig-GI192M11) and $^{60}\rm{Co}$ (Bebig-Co0.A86 $^{60}\rm{Co}$) sources.

	Parameter	¹⁹² Ir	⁶⁰ Co
Simulated Dose (Gy) for optimal audit setup	${}^{5l}D_a$ – Dose to RPLD, 5 cm	1.776 \pm	1.733 \pm
	backscatter with air	0.012	0.006
	${}^{10l}D_a$ – Dose to RPLD, 10 cm	1.785 \pm	1.731 \pm
	back scatter with air	0.011	0.006
	$^{15l}D_a$ – Dose to RPLD, 15 cm	1.783 \pm	1.731 \pm
	back scatter with air	0.012	0.006
	${}^{5h}D_a$ – Dose to RPLD, 5 cm	1.778 \pm	1.733 \pm
	backscatter with steel	0.011	0.006
	$^{10h}D_a$ – Dose to RPLD, 10 cm	1.786 \pm	1.731 \pm
	backscatter with steel	0.011	0.006
	$^{15h}D_a$ – Dose to RPLD, 15 cm	1.783 \pm	$1.732~\pm$
	backscatter with steel	0.012	0.006
	D_w – Dose to water	1.990 \pm	$1.983~\pm$
		0.016	0.006
Simulated Dose (Gy) for	$D_{r,w}$ – Dose to the RPLD in	1.874 \pm	1.757 \pm
correction factors	water	0.016	0.006
	D _{r,p} – Dose to RPLD in PMMA	1.887 \pm	1.749 \pm
	phantom	0.005	0.006
	D_a – Dose in the auditing	1.782 \pm	$1.732~\pm$
	conditions	0.012	0.006
	k_p – Detector perturbation	1.062 \pm	1.129 \pm
	factor	0.013	0.005
Correction factors	k _m – Phantom non-water	0.993 \pm	1.005 \pm
	equivalence factor	0.009	0.005
	k_s – Lack of scatter factor	1.059 \pm	$1.009~\pm$
		0.008	0.005

3.2. Correction factors

The doses derived from simulations and associated correction factors for the setups shown in Fig. 3 were shown in middle and lower sections of Table 2. Type A uncertainty in dose maps was calculated with the history-by-history method resulting in a mean uncertainty of 0.3% per voxel (Supplementary Table 1). The calculated uncertainty for the dose in the RPLD volume was within 0.9%. The total correction factor for the phantom setup in audit conditions (Fig. 3a), which was the product of k_p , k_m and k_s , was 1.117 ± 0.018 for the ¹⁹²Ir source (Bebig-GI192M11) and 1.146 ± 0.005 for the ⁶⁰Co (Bebig-Co0.A86).

3.3. Radiation spectrum analysis

The mean energy in the RPLD volume showed differences within one standard deviation among the 192 Ir source models investigated in the current study. The maximum difference between the 'full scatter' and 'phantom on a table' setup was 17 keV for 192 Ir and 34 keV for 60 Co. The mean energy for 192 Ir was 279 \pm 2 keV and 295 \pm 1 keV for the 'full scatter' and 'phantom on a table' setups, respectively. The corresponding energies for 60 Co were 989 \pm 1 keV and 1022 \pm 1 keV respectively. The simulated spectra for 192 Ir (Bebig GI192M11) and 60 Co (Co0.A86) sources in two different geometries were shown in Fig. 4.

4. Discussion

The phantom, proposed for remote postal brachytherapy dosimetry audits, offers a practical and cost-effective solution. The PMMA material was chosen due to its affordability, durability, and transparency as well as its scattering properties that closely resembles water. RPLD was chosen as the detector because it is already in use for EBRT audits, making it convenient for seamless integration into the existing audit program. The "phantom on a table" with 5 cm water-equivalent material underneath was found as the optimal audit setup. The table material on which the phantom might be placed during the audit had no effect on the dose to the RPLD, with adequate backscatter material. Since, it is postal audit, the proposed phantom was envisaged to be small, lightweight, and easy to transport, that led to its deviation from TG-43 conditions.



Fig. 4. Histograms of Monte Carlo simulated particles with different energies passing through the RPLD for ¹⁹²Ir (Bebig GI192M11) and ⁶⁰Co (Co0.A86) HDR sources in both, the full scatter, and the audit setup. Bins of 10 keV were used.

The determination of correction factors to address non-water equivalence, lack of scatter, and perturbations due to RPLD was necessary, along with the radiation spectral analysis, which was crucial in establishing a reliable dosimetry audit methodology applicable across various HDR source models being used in the hospitals.

To assess the feasibility of conducting audits in hospitals, investigation was carried out to determine the amount of backscatter needed and influence of the underlying table on the RPLD dose, on which the phantom might be positioned. The simulations demonstrated that a 5 cm thick layer of commonly used water-equivalent material, provided adequate backscatter shielding from the table regardless of the thickness and the density of the material. In some other studies 10 cm was assumed as sufficient backscatter but smaller thicknesses were not investigated [27,28].

The G4_WATER was a representation of commercially available plastic water-equivalent materials which might differ in their scattering properties from pure water for low energy particles [29]. This question might be a basis for future simulations or experimental measurements. However, the authors do not anticipate that various commercially available water equivalent material in the hospitals would significantly impact the audit results with the proposed set-up. This expectation was based on the similarity of atomic components in these materials, the predominance of scattered radiation and existing recommendations regarding ¹⁹²Ir dosimetry [17].

The presence of the FD-7 glass rod in a capsule made of HDPE in the PMMA phantom led to significant perturbation effects, resulting in a lower dose (6% for ¹⁹²Ir and 13% for ⁶⁰Co) when compared to TG-43 calculations. This might be attributed to a higher stopping power and density of FD-7 glass than water, which was corrected with the use of the detector perturbation correction factor (k_p). Absorbed dose discrepancies between the TG-43 formalism and the MC simulation in non-water equivalent media was previously reported for HDR sources [30,31].

The physical density and stopping power of PMMA compared to water resulted in 0.7% increase in dose at the detector for ¹⁹²Ir source. Conversely, for the ⁶⁰Co source, the dose simulated in the presence of the PMMA phantom was approximately 0.5% lower even with full scatter conditions. Commercially available water-equivalent materials used for dosimetry might help reducing this discrepancy. A phantom-material correction factor (*k_m*) was necessary to reduce the uncertainty associated with the dose determination.

The phantom was designed to be suitable for postal audits, featuring small size and light weight for easy transport. However, this design resulted in underdosage ranging from 1% for ⁶⁰Co to 6% for ¹⁹²Ir. This under-dosage occurred due to the absence of scatter material around the phantom compared to TG-43 conditions and was already previously reported [32]. Submerging the phantom in a larger water tank mitigated this effect but complicated the auditing procedure. As a result, an

alternative setup with an appropriate "lack of scatter" (k_s) correction factor was applied to obtain dose referencing TG-43.

Deviations from the planned dose, when calculated in a TG-43 based TPS, could be accounted for by applying correction factors k_p , k_m and k_s that were determined basing on the MC simulations from the current study. Experimental validations of the MC simulations, where possible, could support the findings of this study.

The simulations did not address the excitation or light emission response of the RPLDs caused by radiation passing through them and, hence, their innate energy dependence. However, it was important to explore how the energy spectra reaching the RPLDs differed, among the source models used in the hospitals. This was critical, as RPLDs showed an inherent energy dependence [33–35].

The simulations indicated that the HDR ¹⁹²Ir sources were indistinguishable when considered the radiation quality criterion expressed in terms of mean particle energy reaching the detector, which was consistent with a finding of Oliver-Canamas et al. [36]. This was true for both the full scatter and audit setup geometries. However, when the geometry of measurements was changed from full scattering conditions to the audit setup, the mean energy increased by 15-17 keV for ¹⁹²Ir and by 33–34 keV for ⁶⁰Co. This increase in the mean energy might potentially lead to a difference in RPLD sensitivity necessitating energy correction. However, the expected difference was well below the reported uncertainty of RPLD measurements (1.6%, k = 1; [23,24]). The most common HDR sources were simulated in this work, excluding VS2000 and the VariSource [25] as they were not available in Rapid-BrachyMCTPS at the time of investigation. Pulse Dose Rate (PDR) sources were also not part of this investigation. The results are therefore valid only for the investigated source models and future work may need to investigate their validity for other source models.

In the work of Hsu et al. [37], RPLDs did not exhibit energy dependence between the radiation spectra of 192 Ir and 60 Co HDR sources, and Hashimoto et al. [38] reported no differences between the 192 Ir HDR source and a megavoltage photon beam from a linear accelerator at distance of 2 cm.

To conclude, the MC simulations conducted in the study determined the necessary correction factors to account for the lack of scatter and the non-water equivalence of the RPLD and phantom materials, as compared to TG-43 conditions for the HDR sources. The MC simulations identified an optimal audit setup suggesting that a 5 cm thickness of backscatter material was sufficient to mitigate the influence of the table on which the phantom might be positioned during the audits in hospitals. Moreover, the MC simulations demonstrated that the relative mean energy difference in the RPLD among various source models were negligible for both audit setup and in full-scatter conditions, which supports the use of the same correction factors for all ¹⁹²Ir source models, simplifying the dosimetry process. Experimental validation would ensure the accuracy and reliability of the correction factors when applied to practical dosimetry audits.

CRediT authorship contribution statement

Krzysztof Chelminski: Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft. **Alexis Dimitriadis:** Conceptualization, Methodology, Formal analysis, Validation, Writing – original draft. **Roua Abdulrahim:** Formal analysis, Investigation. **Pavel Kazantsev:** Conceptualization, Methodology, Writing – review & editing. **Evelyn Granizo-Roman:** Software, Investigation. **Jonathan Kalinowski:** Software, Formal analysis, Writing – review & editing. **Shirin Abbasi Enger:** Resources, Software, Writing – review & editing. **Godfrey Azangwe:** Methodology, Writing – review & editing. **Mauro Carrara:** Writing – review & editing, Funding acquisition. **Jamema Swamidas:** Conceptualization, Methodology, Project administration, Resources, Funding acquisition, Supervision, Writing – review & editing.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was performed under the framework of the IAEA Coordinated Research Project E2.40.23 "Development of Methodology for Dosimetry Audits in Brachytherapy".

This research was partly enabled by support provided by Calcul Québec (calculquebec.ca) and the Digital Research Alliance of Canada (alliancecan.ca).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi. org/10.1016/j.phro.2024.100657.

References

- [1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. https://doi.org/10.3322/caac.21660.
- [2] Elledge CR, LaVigne AW, Bhatia RK, Viswanathan AN. Aiming for 100% local control in locally advanced cervical cancer: the role of complex brachytherapy applicators and intraprocedural imaging. Semin Radiat Oncol 2020;30:300–10. https://doi.org/10.1016/j.semradonc.2020.05.002.
- [3] Izewska J, Bokulic T, Kazantsev P, Wesolowska P, van der Merwe D. 50 years of the IAEA/WHO postal dose audit programme for radiotherapy: what can we learn from 13756 results? Acta Oncol 2020;59:495–502. https://doi.org/10.1080/ 0284186X.2020.1723162.
- [4] Clark CH, Jornet N, Muren LP. The role of dosimetry audit in achieving high quality radiotherapy. Phys Imaging Radiat Oncol 2018;5:85–7. https://doi.org/ 10.1016/j.phro.2018.03.009.
- [5] Izewska J, Andreo P. The IAEA/WHO TLD postal programme for radiotherapy hospitals. Radiother Oncol 2000;54:65–72. https://doi.org/10.1016/s0167-8140 (99)00164-4.
- [6] Izewska J, Bera P, Vatnitsky S. IAEA/WHO TLD postal dose audit service and high precision measurements for radiotherapy level dosimetry. International Atomic Energy Agency/World Health Organization. Radiat Prot Dosimetry 2002;101: 387–92. https://doi.org/10.1093/oxfordjournals.rpd.a006008.
- [7] Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, et al. Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004;31:633–74. https://doi.org/10.1118/ 1.1646040.
- [8] Croft S, Weaver DR, Matthews R. The thermoluminescence of Toshiba FD-1 and FD-7 RPL glass. Radiat Prot Dosim 1996;65:381–4. https://doi.org/10.1093/ oxfordjournals.rpd.a031666.
- [9] Arakia F, Moribe N, Shimonobou T, Yamashita Y. Dosimetric properties of radiophotoluminescent glass rod detector in high-energy photon beams from a linear accelerator and cyber-knife. Med Phys 2004;31:1980–6. https://doi.org/ 10.1118/1.1758351.

- [10] Sempau J, Kazantsev P, Izewska J, Brualla L. Monte Carlo verification of the holder correction factors for the radiophotoluminescent glass dosimeter used by the IAEA in international dosimetry audits. Phys Med 2021;86:1–5. https://doi.org/ 10.1016/j.ejmp.2021.04.014.
- [11] Dimitriadis A, Chelminski K, Granizo-Roman E, Abdulrahim R, Azangwe G, Swamidas J. PO-2167 Determining a universal reference plan geometry for high dose rate brachytherapy dosimetry audits. Radiother Oncol 2023. https://doi.org/ 10.1016/S0167-8140(23)67082-3.
- [12] Law MY, Liu B. DICOM-RT and its utilization in radiation therapy. Radiographics 2009;29:655–67. https://doi.org/10.1148/rg.293075172.
- [13] Famulari G, Renaud MA, Poole CM, Evans MDC, Seuntjens J, Enger SA. RapidBrachyMCTPS: a Monte Carlo-based treatment planning system for brachytherapy applications. Phys Med Biol 2018;63:175007. https://doi.org/ 10.1088/1361-6560/aad97a.
- [14] Baldwin S. Compute Canada: advancing computational research. J Phys Conf Ser. IOP Publishing; 2012. https://doi.org/10.1088/1742-6596/341/1/012001.
- [15] Badun E, Tessier F, Townson R, Mainegra-Hing E, Storey M-A, Bazalova-Carter M. Introducing the Voxel Interactive Contour Tool for Online Radiation Intensity Analytics (VICTORIA). arXiv preprint arXiv:210514145. 2021. https://doi.org/10. 48550/arXiv.2105.14145.
- [16] Book For Application Developers, Appendix: Geant4 Material Database, NIST Compounds. ver.: 11.2 (doc Rev8.0). Geant4 Collaboration. CERN. Available from: https://geant4-userdoc.web.cern.ch/UsersGuides/ForApplicationDeveloper/html/ Appendix/materialNames.html#geant4-material-database.
- [17] Schoenfeld AA, Harder D, Poppe B, Chofor N. Water equivalent phantom materials for 192Ir brachytherapy. Phys Med Biol 2015;60:9403–20. https://doi.org/ 10.1088/0031-9155/60/24/9403.
- [18] Absorbed Dose Determination in External Beam Radiotherapy. Vienna: International Atomic Energy Agency; 2024. Technical Reports Series No. 398 (Rev. 1). https://doi.org/10.61092/iaea.ve7q-y94k.
- [19] Baltas D, Sakelliou L, Zamboglou N, eds. The Physics of Modern Brachytherapy for Oncology. 2006, CRC Press. https://doi.org/10.1201/9781420012422.
- [20] Bouchard H, Seuntjens J, Carrier JF, Kawrakow I. Ionization chamber gradient effects in nonstandard beam configurations. Med Phys 2009;36:4654–63. https:// doi.org/10.1118/1.3213518.
- [21] Sechopoulos I, Rogers DWO, Bazalova-Carter M, Bolch WE, Heath EC, McNitt-Gray MF, et al. RECORDS: improved Reporting of montE CarlO RaDiation transport studies: Report of the AAPM Research Committee Task Group 268. Med Phys 2018; 45:e1–5. https://doi.org/10.1002/mp.12702.
- [22] BIPM I, IFCC I, ISO I, IUPAP O, eds. Evaluation of measurement data—guide to the expression of uncertainty in measurement, JCGM 100: 2008 GUM 1995 with minor corrections. Joint Committee for Guides in Metrology. Vol. 98. 2008. Available from: https://www.bipm.org/documents/20126/2071204/JCGM_100_2008_E.pdf.
- [23] Dimitriadis A, Kazantsev P, Chelminski K, Titovich E, Naida E, Magnus T, et al. IAEA/WHO postal dosimetry audit methodology for electron beams using radio photoluminescent dosimeters. Med Phys 2023;50:7214–21. https://doi.org/ 10.1002/mp.16776.
- [24] Wesolowska PE, Cole A, Santos T, Bokulic T, Kazantsev P, Izewska J. Characterization of three solid state dosimetry systems for use in high energy photon dosimetry audits in radiotherapy. Radiat Meas 2017;106:556–62. https:// doi.org/10.1016/j.radmeas.2017.04.017.
- [25] Perez-Calatayud J, Ballester F, Das RK, DeWerd LA, Ibbott GS, Meigooni AS, et al. Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO. Med Phys 2012;39:2904–29. https://doi.org/10.1118/1.3703892.
- [26] Walters BR, Kawrakow I, Rogers DW. History by history statistical estimators in the BEAM code system. Med Phys 2002;29:2745–52. https://doi.org/10.1118/ 1.1517611.
- [27] Venselaar JL, van der Giessen PH, Dries WJ. Measurement and calculation of the dose at large distances from brachytherapy sources: Cs-137, Ir-192, and Co-60. Med Phys 1996;23:537–43. https://doi.org/10.1118/1.597811.
- [28] Strohmaier S, Zwierzchowski G. Comparison of (60)Co and (192)Ir sources in HDR brachytherapy. J Contemp Brachytherapy 2011;3:199–208. https://doi.org/ 10.5114/jcb.2011.26471.
- [29] Schoenfeld AA, Thieben M, Harder D, Poppe B, Chofor N. Evaluation of watermimicking solid phantom materials for use in HDR and LDR brachytherapy dosimetry. Phys Med Biol 2017;62:N561–72. https://doi.org/10.1088/1361-6560/ aa9636.
- [30] Badry H, Oufni L, Ouabi H, Hirayama H. A Monte Carlo investigation of the dose distribution for (60)Co high dose rate brachytherapy source in water and in different media. Appl Radiat Isot 2018;136:104–10. https://doi.org/10.1016/j. apradiso.2018.02.016.
- [31] Ait-Mlouk L, Khalis M, Ouabi H, Asnaoui H, Elboukhari S. A Monte Carlo dosimetric parameters of the co high dose rate brachytherapy and investigation of TG43 dose accuracy in different media using GATE v8.2 code. Mosc Univ Phys Bull 2021;76:S68–79. https://doi.org/10.3103/S002713492201012x.
- [32] Nose T, Koizumi M, Yoshida K, Nishiyama K, Sasaki J, Ohnishi T, et al. In vivo dosimetry of high-dose-rate brachytherapy: study on 61 head-and-neck cancer patients using radiophotoluminescence glass dosimeter. Int J Radiat Oncol Biol Phys 2005;61:945–53. https://doi.org/10.1016/j.ijrobp.2004.10.031.
- [33] Lee JH, Lin MS, Hsu SM, Chen IJ, Chen WL, Wang CF. Dosimertry characteristics and performance comparisons: Environmental radiophotoluminescent glass dosemeters versus thermoluminescent dosemeters. Radiat Meas 2009;44:86–91. https://doi.org/10.1016/j.radmeas.2008.10.013.

K. Chelminski et al.

- [34] Nakatake C, Araki F. Energy response of radiophotoluminescent glass dosimeter for diagnostic kilovoltage x-ray beams. Phys Med 2021;82:144–9. https://doi.org/ 10.1016/j.ejmp.2021.01.076.
- [35] Vincke H, Brunner I, Floret I, Forkel-Wirth D, Fuerstner M, Mayer S, et al. Response of alanine and radio-photo-luminescence dosemeters to mixed high-energy radiation fields. Radiat Prot Dosimetry 2007;125:340–4. https://doi.org/10.1093/ rpd/ncm157.
- [36] Oliver-Canamas L, Vijande J, Candela-Juan C, Gimeno-Olmos J, Pujades-Claumarchirant MC, Rovira-Escutia JJ, et al. A user-friendly system for mailed

dosimetric audits of (192)Ir or (60)Co HDR brachytherapy sources. Cancers (Basel) 2023;15. https://doi.org/10.3390/cancers15092484.
[37] Hsu SM, Yeh CY, Yeh TC, Hong JH, Tipton AY, Chen WL, et al. Clinical application

- [37] Hsu SM, Yeh CY, Yeh TC, Hong JH, Tipton AY, Chen WL, et al. Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure. Med Phys 2008;35:5558–64. https://doi.org/10.1118/1.3005478.
- [38] Hashimoto S, Nakajima Y, Kadoya N, Abe K, Karasawa K. Energy dependence of a radiophotoluminescent glass dosimeter for HDR ¹⁹²Ir brachytherapy source. Med Phys 2019;46:964–72. https://doi.org/10.1002/mp.13319.